We are live on ! Find out more
TOVX icon

Theriva Biologics
TOVX

20 hedge funds and large institutions have $836K invested in Theriva Biologics in 2019 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 5 increasing their positions, 2 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more first-time investments, than exits

New positions opened: 3 | Existing positions closed: 1

150% more repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 2

11% more funds holding

Funds holding: 18 → 20 (+2)

0% more ownership

Funds ownership: 0.04% → 0.04% (+0%)

10% less capital invested

Capital invested by funds: $932K → $836K (-$96K)

Holders
20
Holders Change
+2
Holders Change %
+11.11%
% of All Funds
0.44%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
5
Reduced
2
Closed
1
Calls
$2.37M
Puts
–
Net Calls
+$2.37M
Net Calls Change
-$503K

Top Buyers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
+$31.4K
2
Goldman Sachs
Goldman Sachs
New York
+$26.9K
3
SCA
Snowden Capital Advisors
New York
+$22.3K
4
UBS Group
UBS Group
Switzerland
+$13K
5
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$7.25K

Top Sellers

Rank Fund Capital Flow
1
SM
Sabby Management
Florida
-$33K
2
William Blair & Company
William Blair & Company
Illinois
-$483
3
Bank of America
Bank of America
North Carolina
-$121
Name Holding Trade Value Shares
Change 		Change in
Stake
SM
1
Sabby Management
Florida
$379K -$33K -273 -8%
Renaissance Technologies
2
Renaissance Technologies
New York
$228K +$31.4K +260 +15%
WS
3
Wedbush Securities
California
$48K +$4.11K +34 +9%
Goldman Sachs
4
Goldman Sachs
New York
$30K +$26.9K +223 +496%
BFM
5
Boothbay Fund Management
New York
$27K – – –
William Blair & Company
6
William Blair & Company
Illinois
$24K -$483 -4 -2%
SCA
7
Snowden Capital Advisors
New York
$21K +$22.3K +185 New
6CM
8
683 Capital Management
New York
$19K – – –
BlackRock
9
BlackRock
New York
$17K – – –
UBS Group
10
UBS Group
Switzerland
$12K +$13K +108 +5,400%
Susquehanna International Group
11
Susquehanna International Group
Pennsylvania
$11K +$7.25K +60 +150%
Geode Capital Management
12
Geode Capital Management
Massachusetts
$8K – – –
Vanguard Group
13
Vanguard Group
Pennsylvania
$8K – – –
IA
14
IFP Advisors
Florida
$2K +$1.81K +15 New
LTFS
15
Ladenburg Thalmann Financial Services
Florida
$1K – – –
Victory Capital Management
16
Victory Capital Management
Texas
$1K +$1.33K +11 New
Bank of America
17
Bank of America
North Carolina
– -$121 -1 Closed

TOVX Hedge Fund Activity: Q3 2019 in Review

20 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Theriva Biologics (TOVX) for Q3 2019, worth a combined $836K — down 10% from $932K a quarter earlier.

Buyers outnumbered sellers: 3 funds opened new TOVX positions and 1 closed out — a net gain of 2 holders — while 5 added to existing stakes and 2 trimmed.

The largest buyer was Renaissance Technologies, adding an estimated $31.4K. The largest seller was Sabby Management, cutting an estimated $33K.

  • 20 institutional investors held Theriva Biologics (TOVX) as of Q3 2019, up from 18 in Q2 2019.
  • Funds reported $836K of Theriva Biologics stock for Q3 2019, down 10% quarter-over-quarter.
  • 3 funds opened new Theriva Biologics positions in Q3 2019 and 1 closed out, a net change of +2 holders.
  • The largest Theriva Biologics buyer in Q3 2019 was Renaissance Technologies, an estimated $31.4K added.
  • The largest Theriva Biologics seller in Q3 2019 was Sabby Management, an estimated $33K sold.

Based on aggregated 13F filings for Q3 2019.